Encompass Health (NYSE:EHC) Raised to “Buy” at Wall Street Zen

Encompass Health (NYSE:EHC) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Sunday.

Several other equities analysts also recently issued reports on EHC. KeyCorp upped their price objective on shares of Encompass Health from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. Raymond James Financial upgraded shares of Encompass Health to a “strong-buy” rating in a research report on Friday, October 31st. Zacks Research downgraded Encompass Health from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Truist Financial upped their target price on shares of Encompass Health from $135.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday, August 14th. Finally, Barclays boosted their price objective on shares of Encompass Health from $141.00 to $150.00 and gave the stock an “overweight” rating in a research report on Thursday, October 30th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $142.86.

Encompass Health Trading Up 1.5%

EHC opened at $114.44 on Friday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.06 and a current ratio of 1.06. Encompass Health has a one year low of $87.85 and a one year high of $127.99. The company has a market cap of $11.51 billion, a P/E ratio of 21.63, a PEG ratio of 2.20 and a beta of 0.91. The business’s 50-day simple moving average is $121.34 and its 200-day simple moving average is $119.56.

Encompass Health (NYSE:EHC) last announced its quarterly earnings results on Wednesday, March 16th. The company reported $0.93 earnings per share (EPS) for the quarter. Encompass Health had a return on equity of 18.19% and a net margin of 9.33%.The firm had revenue of $136.30 million during the quarter. Encompass Health has set its FY22 guidance at $3.83-$4.19 EPS. As a group, equities research analysts expect that Encompass Health will post 4.8 EPS for the current fiscal year.

Insider Transactions at Encompass Health

In related news, EVP Patrick William Tuer sold 1,020 shares of the company’s stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $123.59, for a total value of $126,061.80. Following the sale, the executive vice president directly owned 18,846 shares of the company’s stock, valued at $2,329,177.14. This represents a 5.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 2.00% of the stock is owned by corporate insiders.

Institutional Trading of Encompass Health

Institutional investors and hedge funds have recently made changes to their positions in the stock. Citizens National Bank Trust Department bought a new stake in Encompass Health in the 3rd quarter valued at about $26,000. WPG Advisers LLC bought a new stake in shares of Encompass Health during the first quarter valued at approximately $27,000. First Horizon Corp acquired a new position in shares of Encompass Health during the third quarter worth approximately $34,000. Westside Investment Management Inc. grew its holdings in Encompass Health by 56.7% in the 3rd quarter. Westside Investment Management Inc. now owns 279 shares of the company’s stock worth $35,000 after buying an additional 101 shares in the last quarter. Finally, Assetmark Inc. increased its position in Encompass Health by 88.1% in the 3rd quarter. Assetmark Inc. now owns 299 shares of the company’s stock valued at $38,000 after acquiring an additional 140 shares during the period. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.